SCHEMBL3353482

SCHEMBL3353482

CC(C)N1CCC(n2ncc3cc(N)ccc32)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
CSNK1A1 P48729 1/20 0.42
GSK3A P49840 1/20 0.42
LIMK1 P53667 1/20 0.42
IKBKE Q14164 1/20 0.42
MAPK14 Q16539 1/20 0.42
TAOK1 Q7L7X3 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
HTR2A P28223 5/20 0.41
HTR7 P34969 5/20 0.41
KCNH2 Q12809 3/20 0.41
DRD2 P14416 2/20 0.39
SCD O00767 1/20 0.39
GPR119 Q8TDV5 7/20 0.38
WEE1 P30291 1/20 0.37
KDM5A P29375 1/20 0.37
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30271240 1.00 CHEK1 (0.42) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL3352822 0.90 HTR1A (0.41) SCDGPR119KDM5ANR3C1ALOX15
SCHEMBL3358945 0.85 ALOX15 (0.52) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL14923489 0.84 CHEK1 (0.47) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL29042132 0.84 HTR7 (0.41) HTR2AHTR7KCNH2DRD2SCD
SCHEMBL21671869 0.83 NR3C1 (0.41) MAPK14HTR2AHTR7KCNH2DRD2
SCHEMBL3352334 0.82 HTR2A (0.45) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL18965035 0.81 NR3C1 (0.47) HTR2AHTR7KCNH2DRD2SCD
SCHEMBL29200978 0.80 KDM4E (0.49) CHEK1AURKADAPK3CSNK1A1GSK3A
SCHEMBL22743605 0.80 HTR2A (0.41) MAPK14HTR2AHTR7KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108623615-B Macrocyclic derivatives of pyrazolo [3,4-d ] pyrimidin-3-one, pharmaceutical compositions and uses thereof 上海迪诺医药科技有限公司 2022-12-13 CN disclosed
EP-3604306-B1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2022-10-26 EP disclosed
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2022-02-15 US disclosed
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2020-12-03 US disclosed
EP-3604306-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai de Novo Pharmatech Co., Ltd. (CN) 2020-02-05 EP disclosed
CN-108623615-A The macrocyclic derivatives, its pharmaceutical composition and application of pyrazoles [3,4-d] pyrimidine -3- ketone 上海迪诺医药科技有限公司 2018-10-09 CN disclosed
EP-2141163-A1 Substituted thiazolidinones, their production and utilisation as medicine Bayer Schering Pharma AG (DE) 2010-01-06 EP disclosed
EP-2141163-A1 Substituted thiazolidinones, their production and utilisation as medicine Bayer Schering Pharma AG (DE) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377520-A1 MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF WEE1, WEE2, PDPK1 CHEK1 27/4885AURKA 1732/4885DAPK3 184/4885
US-11248006-B2 Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof WEE1, WEE2, PDPK1 CHEK1 27/4885AURKA 1732/4885DAPK3 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.